✦ LIBER ✦

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

✍ Scribed by Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman Jr; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono

Book ID: 119609013
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 295 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70379-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7000 ORAL Final Overall Survival (OS) An

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

✍ Fizazi, K.; Scher, H.I.; Molina, A.; Logothetis, C.J.; Jones, R.J.; Staffurth, J 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 58 KB

105 Exploratory analysis of the visceral

105 Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)

✍ Suttmann, H.; Mulders, P.F.A.; Molina, A.; Goodman, O.B.; Flaig, T.W.; Li, J.; K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB

127 Improved survival in elderly (≥75 yr

127 Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study

✍ P.F.A. Mulders; A. Molina; M. Marberger; F. Saad; J.H. Li; T. Kheoh; C.M. Haqq; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 37 KB

1098 ABIRATERONE ACETATE PLUS LOW-DOSE P

1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY

✍ Fizazi, K.; De Bono, J.; Haqq, C.; Logothetis, C.C.; Jones, R.J.; Chi, K.; Kheoh 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 196 KB

Effect of abiraterone acetate and predni

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial

✍ Christopher J Logothetis; Ethan Basch; Arturo Molina; Karim Fizazi; Scott A Nort 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 342 KB

705 ABIRATERONE ACETATE PLUS LOW-DOSE PR

705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY

✍ Saad, Fred; de Bono, Johann S.; Haqq, Christopher M.; Logothetis, Christopher J. 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 56 KB